MeSH Browser

MeSH Heading: Oxyphenbutazone
Tree Number(s): D03.383.129.539.850.777.700
Unique ID: D010113
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D010113
Annotation: a non-steroidal anti-inflamm agent
Scope Note: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27)
Entry Term(s): Diflamil; Hydroxyphenylbutazone; Oxyphenylbutazone; Tanderil
Pharm Action: Anti-Inflammatory Agents, Non-Steroidal
Registry Numbers: H806S4B3NS; 0
Related Numbers: 129-20-4
CAS Type 1 Name: 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl-
NLM Classification #: QV 95
Public MeSH Note: 64
History Note: 64(63)
Date Established: 1964/01/01
Date of Entry: 1999/01/01
Revision Date: 2017/05/24

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0015686
Registry Numbers: H806S4B3NS
Related Numbers: 129-20-4
Scope Note: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27)
Terms: Oxyphenbutazone Preferred Term
Term UI T029912
Date01/01/1999
LexicalTag NON
ThesaurusID; Oxyphenylbutazone
Term UI T029913
Date08/30/1982
LexicalTag NON
ThesaurusID UNK (19XX); Hydroxyphenylbutazone
Term UI T029911
Date04/29/1977
LexicalTag NON
ThesaurusID UNK (19XX)

Oxyphenbutazone MeSH Descriptor Data 2025